Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapyA preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancerQuality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancerPresenters:Prof. Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBernard Doger de Spéville, MD, PhDMedical OncologistSTART-Madrid, Early Phase Clinical Trials UnitHospital Fundación Jiménez DíazMadrid, SpainContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi 

There are no comments yet.

Please log in to write the first comment.